Epic's Antitrust Paradox: Who Should Control The Levers Of Healthcare Innovation?
Forbes
|
Summary
Despite Epic's 36% market share in U.S. hospitals not satisfying monopoly definitions, concerns rise about its dominant position and stifling healthcare innovation impact. Epic attracts top tech talent, offering long-term, game-changing research and development investments, ensuring consumer trust, predictability, and security. Critics argue its significant control over health system and academic medical center markets hinders competition, potentially negatively affecting healthcare expenditure. Epic allegedly employs contracts restricting third-party developers and employees to maintain its intellectual property. Seven areas of conduct are noted for scrutiny, including excessive non-compete clauses, unsustainable fee structures, and bundling practices.
